Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $14.8100 (4.22%) ($14.1400 - $14.8200) on Mon. Feb. 3, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.04% (three month average) | RSI | 68 | Latest Price | $14.8100(4.22%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 2.4% a day on average for past five trading days. | Weekly Trend | TGTX advances 2.6% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(67%) ARKG(60%) IBB(59%) ARKK(58%) IWO(58%) | Factors Impacting TGTX price | TGTX will decline at least -2.52% in a week (0% probabilities). VIXM(-41%) VXX(-40%) TLT(-8%) UUP(-6%) SHY(0%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.52% (StdDev 5.04%) | Hourly BBV | 0 () | Intraday Trend | 3.1% | | | |
|
5 Day Moving Average | $14.39(2.92%) | 10 Day Moving Average | $13.98(5.94%) | 20 Day Moving Average | $13.51(9.62%) | To recent high | 0% | To recent low | 108% | Market Cap | $1.876b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |